Co-requérants du projet (IUMSP): Burnand Bernard & Dusheiko Mark
Collaboratrices et collaborateurs : Pillai Nadia
Ce projet fait partie d’une candidature de PhD (doctorat) à l’Université de Lausanne.
Background & Aims
Crohn’s disease and ulcerative colitis, collectively known as Inflammatory Bowel Disease (IBD), are chronic, autoimmune conditions causing inflammation in the gastrointestinal tract and extra-intestinal complications. The increasing availability of expensive biologic agents has helped improve patient outcomes; however, the extent to which rising treatment costs are offset by improved outcomes and fewer hospitalisations and surgeries still needs to be established. This study aims to assess the health and social costs and benefits of the clinical management of IBD using real world data in Switzerland.
A Markov model will be created to assess the cost-effectiveness of different treatment strategies for adults diagnosed with Crohn’s disease or ulcerative colitis in Switzerland. Reimbursement data will be obtained from health insurance companies in Switzerland, while data on health outcomes and quality of life will be obtained from the Swiss IBD Cohort Study. The results of this model will be compared and validated against results of published economic evaluations.
This will be the first economic evaluation in IBD using data from Switzerland. It will provide evidence on the cost-effectiveness of alternative treatment strategies for IBD as well as insights for clinicians and decision-makers into resource utilisation and the efficiency of IBD management in Switzerland. The research will also contribute to the development of methods to validate economic modelling with observational data from real world clinical practices.